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Background: With improved access to combination anti-
retroviral therapy (cART), children with HIV are growing into
adolescence and adulthood. If the children are deprived of the
knowledge regarding their disease, therewould be signiﬁcant chal-
lenges in coping with the disease. Hence this study was conducted
to assess the various elements of the disclosure of paediatric HIV
status.
Methods&Materials: Focus group discussionswere conducted
in June 2015 among the caregivers of HIV positive children visit-
ing an Anti-Retroviral Therapy (ART) centre in a Southern coastal
city of Karnataka, India. Snowballing method was adopted for
recruitment of the caregivers. The groups consisted of 8 members.
Anonymity was maintained by giving codes for the participants.
The discussions were conducted in Kannada, the ofﬁcial language
of Karnataka. The discussions were voice recorded, transcripts
prepared in English and analysed. Written informed consent was
taken from each participant and Ethical committee clearance was
obtained for the study.
Results: All the caregivers opined that the children have to be
informed about their HIV status mainly for their knowledge and
better adherence to self-care and medications. The caregivers felt
that they themselves have to tell the children at the comforts of
their homes,when the childwas around 7-10 years of age. Amajor-
ity of the participants felt that the children need to be told as a
process over time and not as a discrete one-time event. Theywould
also appreciate the help of the counsellors, especially in answering
the children’s questions. Although improved adherence was seen
in the older children, there were no beneﬁts among the younger
children. The negative aspects of disclosure commonly seen were
negative emotional reactions like sadness, worry or anger which
subsided over time. The children did not face any stigma or dis-
crimination following disclosure.
Conclusion: As there are more beneﬁts than harm from dis-
closing the HIV status to the child, disclosure it should occur as a
slowevolving process over time starting around7-9 years anddone
preferably by the caregivers, assisted by the counsellors. Develop-
ment of culturally appropriate interventions to facilitate disclosure
of HIV status to infected adolescents is key to improve retention,
adherence and other outcomes.
http://dx.doi.org/10.1016/j.ijid.2016.02.565
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Background: AIDS is a chronic, progressive syndrome, charac-
terized by intense viral replication and profound immunosuppres-
sion, resulting in the development of life threatening opportunistic
infections. HIV infection leads to deterioration of immune func-
tions.
The objective of the present study was to develop, optimize and
characterize engineered nanocarriers for controlled delivery of a
protease inhibitor. Lopinavir was the drug of choice as it is an effec-
tive antiretroviral drug having speciﬁc and prominent anti-HIV
action. In the present study, it is envisaged to develop and char-
acterize a controlled delivery system wherein the drug lopinavir
(LPV) will be entrapped in engineered nanocarrier.
Engineered nanocarriers targeted towards the prespeciﬁed tar-
get tissues by coupling with mannose delivers the drug in a
controlled manner to the site of action. Thus it results in increased
bioavailability and avoids the adverse effects associated with the
drug. Overall the approach leads to a safe, economical and effective
Anti-HIV formulation.
Methods & Materials: The uncoupled Solid Lipid Nanoparticles
(SLN)were prepared by Solvent diffusionmethod and then coupled
with mannose. Characterization studies were done by Scanning &
Transmission Electron Microscopy (SEM & TEM). X-ray diffraction
(XRD) and Differential scanning calorimetry (DSC) studies were per-
formed along with the in-vitro studies followed by in-vivo studies on
albino rats.
Results: In-vitro& in-vivo studies results showsMannose coated
SLNs (MSLN) deliver their contents to macrophage rich organs and
tissues, which are the reservoir of HIV. Low elimination and bet-
ter distribution proﬁle can be achieved by MSLNs. The dose of the
antiviral agent can be reduced due to the site-speciﬁc delivery from
this carrier.
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Conclusion: Conclusively, ligand-mediated bio-disposition and
cellular interactionofMSLNs, especially at the target sites,wouldbe
a focal paradigm for upcoming research in the ﬁeld of anti-HIV drug
delivery.MSLNs have paved theway for the bio-stable, site-speciﬁc
and ligand-mediated delivery systems with desired therapeutics.
http://dx.doi.org/10.1016/j.ijid.2016.02.566
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Prevalence and risk factors associated with
immunological non-response in HIV-1 infected
patients treated with NNRTI based ﬁrst line
drugs in South India
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Background: The absence of a recovery in the CD4+ T cell
count during long-term, virologically suppressive HAART is an
unquestionable source of anxiety toHIV-infected patients and their
treating clinicians, given the long-term risks of disease progression
and death, underscoring the need for means of identifying early
predictive factors and treatment options.
Methods&Materials: To study theprevalence, risk factors asso-
ciated to immunological non-responders (INR), and T-cell recovery
pattern, we cross-sectionally analyzed 522 HIV patients on NNRTI
basedﬁrst lineHAART at 6th month and12th month during therapy.
Results: Among 522 HIV patients, we found 56 (10.72%) each
failed to achieve at least 50 cells after 6 months and 100 cells after
12 months of HAART. Lower baseline viral load (median 4.4 log
10 copies, IQR 3.80 – 4.88,p <0.0001), higher baseline CD4 count
(median 309.5cells/L , IQR 229.2 - 386.7, p <0.05), high nadir CD4
count (median 260cells/L, IQR 219.5 - 319.5, p <0.05) was found
to be the independent risk factor. Patient initiating ART when CD4
count was >350 CD4 T-cell count (n=130) comprised more INR, fol-
lowed by CD4 count of 200 – 350 cells, then <200 cells (p value
<0.05).
Conclusion: Despite the suppressed viral load, signiﬁcant pro-
portion of patients found to have low CD4 recovery and associated
with high baseline /nadir CD4 count and lower baseline viral load.
Understanding the pathophysiologic mechanisms responsible for
this immune disconnect could be explored in clinical practice for
the most effective management of discordant patients to improve
the clinical outcome.
http://dx.doi.org/10.1016/j.ijid.2016.02.567
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Prevalence of genital herpes in HIV positive
patients attending STI clinic at a tertiary care
hospital and its correlation with CD4 counts
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Background: HIV infection is emerging as one of the major
health problems faced by the clinicians across the world, more
so because of co-existence of many sexually transmitted infec-
tions (STIs) amongHIV infected patients. The presence of untreated
STIs (both ulcerative and non-ulcerative) increases the risk of both
acquisition and transmission of HIV by a factor of upto 10 times.
Recurrent and persistent ulcerative HSV2 lesions are among the
common infections in HIV patients. Prevalence of genital herpes
has increased markedly between the 1970’s and 1990’s. Hence it
is important to promptly diagnose and treat genital herpes which
thus concurrently reduces the transmission of HIV
Methods & Materials: A detailed history of 200 retropositive
patientswith regard toname, age, sex,natureanddurationof illness
was noted. Photographs of the lesions were taken for documen-
tation. Diagnosis of herpes genitalis was done mainly on clinical
grounds Tzanck smear and HSV2 IgM antibody titers were done. To
rule out other causes of genital ulceration, samples were sent for
appropriate microbiological investigations. CD4 T cell counts were
done
The resultswere tabulated and appropriate statistical testswere
done
Results: Out of 200 retropositive patients 52 (25.5%) presented
with STIs among which 30 had genital herpes (15%). It was more
commonly seen in the age group of 30-40 years, married couples
and patients having multiple partners. Tzanck smear and IgM anti
HSV2 positivity was seen in 43% and 48% of patients respectively.
Average CD4 count of 297cell/cu.mm was seen.
Conclusion: Trendof STI’s has gradually changedover the years,
with decline in incidence of bacterial STI’s & increase in the preva-
lence of viral STI’s most commonly genital herpes. HIV and herpes
genitalis coinfection increases the transmission of each other.
http://dx.doi.org/10.1016/j.ijid.2016.02.568
